ArticleInternational journal of general medicine2022
New Antifibroblastic Medication in Dermatology: Could Nintedanib Treat Scarring?
Article in International journal of general medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- Pirfenidone-exosomes as innovative strategies for scarless tissue repair in wound healing.Drug delivery and translational research · 2026Article
- Erosive pustular dermatosis: Rapid clearance with nintedanib.JAAD case reports · 2026Article
- Therapeutic Anti-Fibrotic Effects of a Dual Hyaluronic Acid Hybrid Complex in Bleomycin-Induced Dermal Fibrosis and UVB-Irradiated Human Skin.International journal of molecular sciences · 2026Article
- Deciphering the cellular landscape of pathological scars.Burns & trauma · 2026Article
- LangerinClinical, cosmetic and investigational dermatology · 2025Review
- The Association of Telangiectasias with Other Peripheral Vascular Lesions of Systemic Sclerosis.Clinical, cosmetic and investigational dermatology · 2024Article
- Review
- Immunologic and nonimmunologic sclerodermal skin conditions - review.Frontiers in immunology · 2023Review
- Evaluation of the effectiveness of oral Pirfenidone in the treatment of oral submucous fibrosis: A non-randomised pilot clinical trial.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are a wide variety of disfiguring dermatological conditions whose pathologic substrate is represented by the unwanted deposition of collagen from dermal fibroblasts. Pirfenidone has demonstrated efficiency in the treatment of disordered collagen production when applied topically. Due to a similar mechanism of action, we also hypothesize that a similar medication, nintedanib, might have similar applications. We also propose that a liposomal technology may assist in the penetration of nintedanib and enhance its clinical effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.